Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration.
Pasteuning-Vuhman S, Boertje-van der Meulen JW, van Putten M, Overzier M, Ten Dijke P, Kiełbasa SM, Arindrarto W, Wolterbeek R, Lezhnina KV, Ozerov IV, Aliper AM, Hoogaars WM, Aartsma-Rus A, Loomans CJ. Pasteuning-Vuhman S, et al. Among authors: van putten m. FASEB J. 2017 Jan;31(1):238-255. doi: 10.1096/fj.201600675R. Epub 2016 Oct 12. FASEB J. 2017. PMID: 27733450 Free PMC article.
Therefore, caution must be used when developing therapies that interfere with MSTN/activin pathways.-Pasteuning-Vuhman, S., Boertje-van der Meulen, J. W., van Putten, M., Overzier, M., ten Dijke, P., Kielbasa, S. M., Arindrarto, W., Wolte …
Therefore, caution must be used when developing therapies that interfere with MSTN/activin pathways.-Pasteuning-Vuhman, S., Boertje-van …
Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD).
Nadarajah VD, van Putten M, Chaouch A, Garrood P, Straub V, Lochmüller H, Ginjaar HB, Aartsma-Rus AM, van Ommen GJ, den Dunnen JT, 't Hoen PA. Nadarajah VD, et al. Among authors: van ommen gj, van putten m. Neuromuscul Disord. 2011 Aug;21(8):569-78. doi: 10.1016/j.nmd.2011.05.011. Epub 2011 Jul 2. Neuromuscul Disord. 2011. PMID: 21724396 Free article.
Comparison of skeletal muscle pathology and motor function of dystrophin and utrophin deficient mouse strains.
van Putten M, Kumar D, Hulsker M, Hoogaars WM, Plomp JJ, van Opstal A, van Iterson M, Admiraal P, van Ommen GJ, 't Hoen PA, Aartsma-Rus A. van Putten M, et al. Among authors: van ommen gj, van opstal a, van iterson m. Neuromuscul Disord. 2012 May;22(5):406-17. doi: 10.1016/j.nmd.2011.10.011. Epub 2012 Jan 27. Neuromuscul Disord. 2012. PMID: 22284942 Free article.
The effects of low levels of dystrophin on mouse muscle function and pathology.
van Putten M, Hulsker M, Nadarajah VD, van Heiningen SH, van Huizen E, van Iterson M, Admiraal P, Messemaker T, den Dunnen JT, 't Hoen PA, Aartsma-Rus A. van Putten M, et al. Among authors: van huizen e, van iterson m, van heiningen sh. PLoS One. 2012;7(2):e31937. doi: 10.1371/journal.pone.0031937. Epub 2012 Feb 16. PLoS One. 2012. PMID: 22359642 Free PMC article.
Low dystrophin levels in heart can delay heart failure in mdx mice.
van Putten M, van der Pijl EM, Hulsker M, Verhaart IE, Nadarajah VD, van der Weerd L, Aartsma-Rus A. van Putten M, et al. Among authors: van der weerd l, van der pijl em. J Mol Cell Cardiol. 2014 Apr;69:17-23. doi: 10.1016/j.yjmcc.2014.01.009. Epub 2014 Jan 29. J Mol Cell Cardiol. 2014. PMID: 24486194 Free article.
326 results